Literature DB >> 11594710

Osteosarcoma as a second malignancy after treatment for neuroblastoma.

A Iwata1, T Hirota, K Konno, T Fujimoto, S Sumida, K Sato, K Hara.   

Abstract

A 4-month old girl was diagnosed as having stage IV neuroblastoma of the right adrenal gland. Preoperative chemotherapy was given, followed by local surgical excision. Postoperatively, irradiation of the tumor bed and adjuvant chemotherapy was given for 11 months. Nine years after cessation of chemotherapy, the patient developed left hip-joint pain. Biopsy of the ischium showed chondroblastic osteosarcoma. Limb salvage surgery was performed after preoperative chemotherapy. Postoperatively, adjuvant chemotherapy was given for 14 months. Twenty-two months after treatment for the secondary osteosarcoma, the patient has been remained in disease-free condition without any evidence of relapse. A second osteosarcoma occurring outside the radiation field after treatment for neuroblastoma is quite rare. This unusual case emphasized the need for close monitoring for development of second malignant neoplasms in survivors of neuroblastoma even in the absence of a known predisposing factor, such as radiation therapy.

Entities:  

Mesh:

Year:  2001        PMID: 11594710     DOI: 10.1080/088800101750476050

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  2 in total

1.  Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma.

Authors:  Sara M Federico; Heather B Allewelt; Sheri L Spunt; Melissa M Hudson; Jianrong Wu; Catherine A Billups; Jesse Jenkins; Victor M Santana; Wayne L Furman; Lisa M McGregor
Journal:  J Pediatr Hematol Oncol       Date:  2015-01       Impact factor: 1.289

2.  The prognosis of osteosarcoma occurring as second malignancy of childhood cancers may be favorable: experience of two cancer centers in Japan.

Authors:  Tsukasa Yonemoto; Ako Hosono; Shintaro Iwata; Hiroto Kamoda; Yoko Hagiwara; Tomohiro Fujiwara; Akira Kawai; Takeshi Ishii
Journal:  Int J Clin Oncol       Date:  2014-07-15       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.